STERIS

STE · NYSE

$225.18+$3.21 (+1.45%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $221.97

STE analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy3
Hold0
Underperform0
Sell0

12-month price target · 11 analysts

Average $271.12 (+20.4% upside)

Low: $234.32
Now: $225.18
High: $300.30

Upgrades and downgrades

The latest rating actions, newest first

STE analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
UBS	Aug 7, 2026	Maintains	Buy	$275.00 → $270.00	43%
Piper Sandler	Aug 7, 2026	Maintains	Overweight	$270.00 → $275.00	43%
UBS	Jul 28, 2026	Initiates	Buy	$275.00	43%
Keybanc	May 13, 2026	Maintains	Overweight	$291.00 → $269.00	56%

The case for and against

Updated Oct 18, 2026

Bull case

Steris is benefiting from a durable, high-quality demand profile, with FQ1-27 revenue in line and EPS beating by a dime, while Healthcare organic growth reached 6% on 10% service growth and 9% consumables growth. Its global contract sterilization leadership and recurring service base support resilient execution, as Healthcare services have run at double-digit levels for 14 consecutive quarters and segment EBIT margin expanded 60 bp to 24.8%. Visibility is also improving through 8% Healthcare equipment orders, backlog at a 3-year high of $444M, and management’s confidence in AST growth accelerating as FY'27 progresses, while the $600M North Carolina investment signals long-term capacity and margin expansion.

Bear case

Steris is a high-quality sterilization leader, but the outlook is negative because the latest quarter showed uneven core execution: Healthcare Services and AST both missed growth expectations, while only LifeSci outperformed. Although revenue rose 6.2% cc organic to $1,493M and EPS beat at $2.59, the company’s outlook weakens as capex was raised from $375M to $450M for the new NC facility and free cash flow guidance was cut to $800M from $850M. The stock also faces macro and regulatory risks, including sensitivity to procedure volumes, inflation and supply chain pressure, plus potential adverse tariff and FDA actions, which could constrain margin durability and growth.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.